Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
2 Biotech Stocks That Could Help Make You a Fortune
10:15am, Saturday, 30'th Jul 2022 The Motley Fool
These companies have seen triple-digit revenue growth in recent years.
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
02:03pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
04:47pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.
GSK Gears Up to Report Q2 Earnings: What's in the Cards?
02:59pm, Monday, 25'th Jul 2022 Zacks Investment Research
The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company report
3 Cheap Stocks To Buy Now
03:30pm, Tuesday, 12'th Jul 2022 The Motley Fool
COVID fighters and crypto brokers are super-cheap right now.
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
02:47pm, Monday, 27'th Jun 2022 Zacks Investment Research
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
11:00am, Saturday, 25'th Jun 2022 GlobeNewswire Inc.
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signal
Buy the Dip on These 3 Healthcare Stocks
03:25pm, Sunday, 19'th Jun 2022 The Motley Fool
Here's why our roundtable likes Vir Biotechnology, OrthoPediatrics, and Vertex Pharmaceuticals.
Buy the Dip on These 3 Healthcare Stocks
11:25am, Sunday, 19'th Jun 2022
Here's why our roundtable likes Vir Biotechnology, OrthoPediatrics, and Vertex Pharmaceuticals.
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
11:34am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accep
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
08:03pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20,
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
07:05pm, Wednesday, 18'th May 2022 Zacks Investment Research
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
07:00pm, Thursday, 12'th May 2022 Benzinga
Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc
Where Vir Biotechnology Stands With Analysts
01:27pm, Friday, 06'th May 2022 Benzinga
Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
0
1
0
0
Las
Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat Estimates
09:25pm, Thursday, 05'th May 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
